Shopping Cart

Efficacy of Chelidonium Majus on Liver Complaint – Schwabe News

Efficacy of Chelidonium majus on liver complaint

This study was conducted to evaluate the efficacy of Chelidonium majus (Chel) 30CH and 200CH in amelioration of experimentally induced hepato-toxicity in rats. Rats were randomized into six sub-groups: negative control; negative control+EtOH (ethanol); positive control; positive control+EtOH (ethanol) group; Chelidonium majus 30; Chelidonium majus 200. Different toxicity biomarkers and pathological parameters were evaluated after 30, 60, 90 and 120 days. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), lactate dehydrogenase (LDH), triglyceride, cholesterol, creatinine and bilirubin were elevated from chronic feeding of  p-dimethyl amino azo benzene (p-DAB) and phenobarbital (PB) and lowered the levels of glutathione (GSH), glucose-6-phosphate dehydrogenase (G-6-PD), catalase and HDL-cholesterol. In the treated animals parameters were statistically significant in comparison with positive controls. Downregulation of metalloproteinases were observed in treated groups. The favourable modulations in most endpoints in the Chelidonium majus treated rats suggest that Chelidonium majus 30 and Chelidonium majus 200CH had similar protective effects against p-DAB+PB induced hepatocarcinogenesis, although Chelidonium majus 200CH appeared to have slightly better effects at the later time points. From the study it was concluded that Chelidonium majus exhibited anti-tumour and anti-oxidative stress potential against artificially induced hepatic tumours and hepato-toxicity.


Antara Banerjee, Surajit Pathak, Surjyo Jyoti Biswas, Susanta Roy-Karmakar, Naoual Boujedaini, Philippe Belon, Anisur Rahman Khuda-Bukhsh. Chelidonium majus 30C and 200C in induced hepato-toxicity in rats.  Homeopathy 2010; 99(03): 167-176 DOI: 10.1016/j.homp.2010.05.008.

Share this news
schwabe exit popup banner